Review Article

The Spectrum of Genetic Defects in Chronic Lymphocytic Leukemia

Davide Rossi,1 Marco Fangazio1 and Gianluca Gaidano1

1 Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

Correspondence to: Davide Rossi, M.D., Ph.D., Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; Tel: +39-0321-660698; Fax: +39-0321-620421; E-mail rossidav@med.unipmn.it

Competing interests: The authors have declared that no competing interests exist.

Abstract. Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and shows a remarkable heterogeneity in the clinical course. Understand the genetic basis of CLL may help in clarifying the molecular bases of this clinical heterogeneity. Recurrent chromosomal aberrations at 13q14, 12q, 11q22-q23 and 17p13, and TP53 mutations are the first genetic lesions identified as drivers of the disease. While some of these lesions are associated with poor outcome (17p13 deletion, TP53 mutations and, to a lesser extent, 11q22-q23 deletion) others are linked to a favorable course (13q14 deletion as sole aberration). Recently, next generation sequencing has revealed additional recurrent alterations in CLL targeting the NOTCH1, SF3B1, and BIRC3 genes. NOTCH1, SF3B1, and BIRC3 lesions provide: i) new insights on the mechanisms of leukemogenesis, tumor progression and chemoresistance in this leukemia; ii) new biomarkers for the identification of poor risk patients, having individually shown correlations with survival in CLL; and iii) new therapeutic targets, especially in the setting of high risk disease. This review will summarize the most important genetic aberrations in CLL and how our improved knowledge of the genome of leukemic cells may translate into improved patients' management.

Introduction. In Western countries, chronic lymphocytic leukemia (CLL) is the most frequent mature B-cell malignancy.1,2 The course CLL ranges from very indolent, with a nearly normal life expectancy, to rapidly progressive leading to early death.3,4 Understand the genetic basis of CLL may help in clarifying the molecular determinants of this clinical heterogeneity and improve patients' prognostication.

Recurrent chromosomal aberrations at 13q14, 12q, 11q22-q23 and 17p13 are the first genetic lesions identified as drivers of the disease, and has enabled the construction of a hierarchical model of cytogenetic abnormalities that correlates with outcome.9 Cytogenetic lesions, however, may not entirely explain the genetic basis of CLL clinical heterogeneity, as documented by the contribution of TP53 mutation assessment in identifying high risk patients.9 The recent major improvements in massive parallel sequencing technologies have provided an opportunity to examine the CLL genome, allowing for the identification of
genomic alterations underlying the disease and for the discovery of new therapeutic targets and clinically predictive biomarkers such as NOTCH1, SF3B1 and BIRC3.10,16

Prevalence of Genetic Lesions at Different CLL Clinical Phases. During its history, CLL may proceed through distinct clinical phases, ranging from a pre-malignant condition known as monoclonal B-cell lymphocytosis (MBL), to overt CLL, and even transformation into an aggressive lymphoma (Richter syndrome).1,2

Similarly to other pre-malignant conditions, also MBL frequently harbor genetic changes that can be found in the overt disease. In MBL, 13q14 deletion occurs at the same prevalence as in overt CLL (~40-50% of cases), even when the number of circulating monoclonal CLL-like cells is extremely small, thus indicating that this lesion occurs early during the natural history of the disease.17,21 What distinguishes MBL from CLL is the rate of occurrence of genetic lesions that are considered secondary events and that associate with poor outcome in this leukemia.17,21 In clinical MBL, 11q22-q23 deletion, 17p13 deletion and mutations of BIRC3, TP53, NOTCH1 and SF3B1 may be observed in ~1-3% of cases, a prevalence that is significantly lower than that of CLL (Table I).17,19,21,22

High risk cytogenetic abnormalities have been occasionally described also in low count MBL, but the biological implications of this observation are currently unknown.18,20

When CLL is overt, three major clinical phases can be envisaged, including: i) newly diagnosed CLL; ii) progressive CLL; and iii) relapsed and fludarabine-refractory CLL (Table I).2 TP53 abnormalities, including mutations and 17p13 deletions, are observed in ~5-10% newly diagnosed CLL, in ~10% progressive CLL requiring first treatment,9,23-32 and in ~40-50% relapsed and fludarabine-refractory CLL,33-35 thus representing the most frequent lesions in this high risk clinical condition. Deletion of 11q22-q23 occurs in 10-15% in newly diagnosed CLL,9,36 while its prevalence raises to 20-25% at the time of first treatment and 25-30% at fludarabine-refractoriness.24,29,33,34 Mutations of ATM, which is included in the minimal common region of deletion on 11q22-q23, have been shown to be present in 12% of newly diagnosed patients and in 15% progressive CLL requiring first treatment.37-40 By combining mutations and deletions, genetic lesions of ATM occur in 25% of diagnostic samples of CLL and in 37% cases requiring first treatment.37-40 These frequencies make ATM alterations the most common genetic lesions predicting poor outcome at CLL presentation and treatment requirement.

Among the novel genetic alterations disclosed by whole genome/exome sequencing, NOTCH1, SF3B1 and BIRC3 lesions follows the same distribution across CLL clinical phases as TP53 and ATM abnormalities (Table I). NOTCH1 mutations recur in ~10% unselected newly diagnosed CLL while their prevalence increases to 15-20% in progressive and relapsed cases.10,11,14 SF3B1 mutations have been identified in ~7% unselected newly diagnosed CLL, while their prevalence rises to 17% in relapsed and fludarabine-refractory patients.12,13,16 BIRC3 lesions occur at low rate (4% of cases) in unselected newly diagnosed CLL, while are enriched among relapsed and fludarabine-refractory CLL (24% of cases).15

Because of their recent identification and the lack of information from large clinical trials, the precise rate of occurrence of NOTCH1, BIRC3, and SF3B1 lesions at the time of first treatment requirement still remains to be clarified.

Within the spectrum of the various aspects of CLL, Richter syndrome (RS) is the most aggressive clinical phenotype because of the combined effect of chemoresistance and rapid disease kinetics. The clinical behavior of RS is strongly related to its genetic background (Table I). The high rate of TP53 abnormalities, which occur in ~60% cases and represent the most frequent genetic lesion at the time of transformation, accounts for the chemoresistance that is very common in RS.41 NOTCH1 mutations are the second most frequent genetic lesion in RS, where they occur in ~30% of cases.10 Among the other high risk genetic lesions, ATM abnormalities, BIRC3 genetic lesions and SF3B1 mutations that are otherwise enriched at the time of chemorefractoriness are rare or absent in RS, thus strengthening the notion that RS is molecularly distinct from chemorefractory progression without transformation.13,14,41

Table 1. Prevalence of CLL recurrent lesion stratified according the disease phase

|                | TP53 disruption | del 11q22-q23 | NOTCH1 mutations | SF3B1 mutations | BIRC3 disruption |
|----------------|-----------------|---------------|------------------|-----------------|-----------------|
| MBL            | 1-2%            | 0-3%          | 3%               | 1-2%            | 0               |
| Diagnosis      | 5-10%           | 10-15%        | 8-11%            | 4-7%            | 0.05            |
| First treatment| 10-11%          | 20-25%        | 10-15%           | 17%             | n.a.            |
| Chemorefractoriness | 40-50%       | 25-30%        | 15-20%           | 17%             | 25%             |
| Richter Syndrome | 50-60%     | 10%           | 30-40%           | 0%              | 0               |
| CLL, Chronic lymphocytic leukemia, MBL, Monoclonal B-cell lymphocytosis | | | | | |
TP53 Abnormalities. The tumor suppressor gene TP53 codes for a central regulator of the DNA-damage-response pathway, and its activation leads to cell-cycle arrest, DNA repair, apoptosis, or senescence through both transcription-dependent and transcriptional-independent activities. Among CLL harboring TP53 abnormalities, mutations of TP53 co-occurred with deletion of the corresponding locus in ~70% of cases, consistent with a dual hit mechanism of inactivation. The remaining ~30% of cases have 17p13 deletion in the absence of TP53 mutations (~20%), or TP53 mutations in the absence of 17p13 deletion (~10%). TP53 mutations are mainly represented by missense substitutions targeting the DNA-binding domain, while the remaining are truncating lesions. Mutations either directly disrupt the DNA binding domain of TP53 or cause conformational changes of the TP53 protein, thus leading to severely impaired TP53 function.

The clinical importance of TP53 abnormalities in CLL is tightly linked to their close association with poor outcome and refractoriness, as documented by a number of observational studies and prospective trials led in both the chemotherapy and immunotherapy era. Among unselected newly diagnosed CLL, patients harboring 17p13 deletion have an estimated median overall survival (OS) of only 3-5 years. However, it is important to stress that there is a small subgroup of patients with 17p13 deletion (and mostly mutated immunoglobulin genes) who may exhibit stable disease for years without treatment indications.

The outcome of patients with 17p13 deletion and need for treatment is very poor. With the most effective regimen available today for CLL, i.e. FCR (fludarabine-cyclophosphamide-rituximab), patients with 17p13 deletion have a poor response (5% of complete response vs ~50% in non 17p13 deleted CLL), a short progression free survival (PFS) (11.2 months vs 51.8 months) and OS (38.1% at 36 months). This is in line with the established importance of the wild-type TP53 protein in mediating the cytotoxicity of DNA-damaging agents including purine analogs.

A number of prospective studies suggest that, in addition to 17p13 deletion, also TP53 mutations, even in the absence of 17p13 deletion, predict poor outcome in CLL. In the GCLeSG CLl4 trial (fludarabine vs fludarabine-cyclophosphamide) no complete response were observed in TP53 mutated CLL, and the median PFS (23.3 vs 62.2 months) and OS (29.2 vs 84.6 months) were significantly shorter in the group with TP53 mutation. In the GCLeSG CLl8 trial (fludarabine-cyclophosphamide vs FCR), patients with TP53 mutations showed the lowest complete response and overall response rates (6.9% vs. 36.4% and 62.1% vs. 95.3%), translating into shorter PFS (12.4 months vs. 45 months) and OS (39.3 months vs not reached in all other patients). In the UK LRFL CLl4 trial (chlorambucil vs fludarabine vs fludarabine-cyclophosphamide), the complete response rate of TP53 mutated patients was only 5% with a 5-years PFS of 5% and a 5-years OS of 20%.

Based on these data, 17p13 deletion is the sole cytogenetic abnormality that is recommended to be tested by FISH in CLL patients requiring treatment. Since CLL with TP53 mutations experience poor prognosis regardless of the presence of 17p13 deletion, the TP53 mutation analysis should be integrated into the evaluation of CLL patients before treatment initiation. CLL patients carrying TP53 alterations, regardless of whether mutated or deleted, should be redirected to different therapeutic regimens compared to the standard chemo/chemoimmunotherapies.

NOTCH1 Mutations. The NOTCH1 gene encodes a heterodimeric transmembrane protein that functions as a ligand-activated transcription factor with a high conserved pathway. When the NOTCH1 receptor interacts with its ligands through the extracellular subunit, two consecutive proteolytic cleavages of the protein are initiated and lead to pathway activation. The S2 cleavage in the heterodimerization domain is performed by ADAM10, and is followed by the S3 cleavage by the γ-secretase complex. Upon activation the cleaved intracellular portion of NOTCH1 (ICN) translocates into the nucleus where it modifies the expression of target genes, including the MYC oncogene. As a transcriptional factor, NOTCH1 plays an important role in a number of cellular functions during embryogenesis and in self-renewing tissues of the adult organism, including maintenance of stem cells, cell fate specification, proliferation, and apoptosis. One of the mechanisms of the NOTCH1 signal suppression is operated through the PEST [proline (P), glutamic acid (E), serine (S), and threonine (T) rich] domain that directs the activated NOTCH1 towards proteosomal degradation. A major role of NOTCH1 in lymphoid cells in the adult organism is the commitment of hematopoietic progenitors to differentiate toward T lineage. Conversely, in mature B-lymphocytes, NOTCH1 signaling promotes terminal differentiation to antibody-secreting cells.

NOTCH1 mutations were the first molecular lesion identified through massive parallel next generation sequencing in CLL by two independent groups. NOTCH1 mutations are significantly more frequent in CLL with unmutated, rather than mutated,
immunoglobulin genes, are significantly enriched in CLL harboring trisomy 12, and identify a distinct clinico-molecular subgroup of CLL with deregulated cell cycle and short survival.10,12,14,16,51-53

NOTCH1 mutations in CLL mainly clusters within a hotspot in exon 34, and are commonly represented by a single 2-bp deletion (c.7544_7545delCT) that accounts for ~80-95% of all NOTCH1 mutations in this leukemia (Figure 1).10-12,14,16,51-53 The predicted functional consequence of NOTCH1 mutations in CLL is the disruption of the C-terminal PEST domain resulting in activated NOTCH1 protein, impaired degradation and accumulation, and sustaining deregulated signaling.11 Consistent with this notion, a number of cellular pathways are specifically altered in CLL harboring NOTCH1 mutations.11,52

Beside their pathogenetic role, NOTCH1 mutations also represent a new biomarker for the identification of poor risk CLL patients. NOTCH1 mutated patients have a rapidly progressive disease and a significantly shorter survival probability (21-45% at 10 years) compared to NOTCH1 wild type cases (56-66% at 10 years).10,11,14 The poor prognosis associated with NOTCH1 mutations in CLL may be explained, at least in part, by a substantial risk (~40-50%) of developing Richter syndrome.10,11,14

NOTCH1 is a potential therapeutic target in CLL. Treatment with γ-secretase inhibitors induces apoptosis of CLL cells by inhibiting the enzymatic S3 cleavage necessary for NOTCH1 activation.37,54,55 However, the limitations due to toxicity of γ-secretase inhibitors in the clinical setting suggest that alternative strategies may be needed for the therapeutic targeting of NOTCH1.

SF3B1 Mutations. The spliceosome machinery, a complex of five small nuclear ribonucleoproteins (snRNPs), contributes to the formation of mature mRNA through the removal of introns in the precursor messenger RNA (pre-mRNA) of protein-encoding genes, and is involved in both normal and alternative mRNA splicing.10-12

SF3B1 is a core component of the U2 snRNP that recognizes the 3’ splice site at the intron-exon junctions.56,58-61 Structurally, the SF3B1 protein has two well-defined regions: i) the N-terminal amino acid region which contains several protein-binding motifs and functions as a scaffold to facilitate its interaction with other splicing factors; and ii) the C-terminal region which contains 22 non-identical tandem repeats of the HEAT motif that meander around the SF3b complex.56,58-61

Whole genome/exome sequencing technologies allowed for the identification of SF3B1 as a recurrently mutated gene in CLL.12,13,16 SF3B1 mutations in CLL cluster in selected HEAT repeats of the SF3B1 protein, target a number of hotspots (codons 662, 666, 700, 742), and are generally represented by missense substitutions (Figure 1).12,13,16 Notably, an identical spectrum of SF3B1 mutations has been identified in other hematopoietic tumors of the myeloid compartment.62

The precise biological consequences of SF3B1 mutations in CLL are currently unknown. However, the clustering of SF3B1 mutations within the HEAT domains suggests that they are selected to modify SF3B1 interactions with other proteins of the spliceosome complex, thus resulting in deregulated normal and alternative mRNA splicing.12,16

Consistent with their accumulation in the more advanced phases of the disease, SF3B1 mutated patients show a significantly shorter overall survival (34-48% at 10 years) compared to wild type cases (60-73% at 10-years).12,13,16

BIRC3 Abnormalities. In CLL, activation of the NF-κB pathway contributes to the acquisition of a chemorefractory clinical phenotype and correlates with poor outcome.63-67 The Baculoviral IAP repeat containing 3 (BIRC3) gene is one of the components of a protein complex that negatively regulates the MAP3K14 serin-threonine kinase, the downstream activator of non-canonical NF-κB signaling.63-66

BIRC3 was found to be recurrently disrupted by mutations, deletions, or a combination of mutations and deletions in CLL patients.15 BIRC3 inactivating mutations and a fraction of BIRC3 deletions cause a truncation of the C-terminal RING domain of the BIRC3 protein, essential for ubiquitination, and the following proteasome degradation, of MAP3K14, and drives constitutive non-canonical NF-κB activation (Figure 1).15

The BIRC3 gene maps to 11q22.2, approximately 6Mb centromeric to the ATM locus. The identification of BIRC3 involvement in CLL might be important for elucidating the molecular genetics of 11q22-q23 deletion, a frequent cytogenetic abnormality predictive of poor outcome. In fact, although ATM has been regarded as the relevant gene of this chromosomal abnormality, biallelic inactivation of ATM does not exceed ~30% of cases with 11q22-q23 deletion.36-39 The presence of an additional tumor suppressor in the 11q22-q23 region has been postulated,40 and BIRC3 implicates a suitable candidate.

From a clinical standpoint, BIRC3 lesions contribute to clinical aggressiveness and fludarabine refractoriness in CLL.15 Indeed, BIRC3 lesions identify a subgroup of CLL displaying poor survival.
(median 3.1 years) similar to that associated with TP53 abnormalities.\(^5\)

In CLL, fludarabine refractoriness may be explained by TP53 disruption in ~40% of patients, while ~60% high risk CLL do not present TP53 abnormalities.\(^5\) Intriguingly the distribution of BIRC3 disruption and TP53 abnormalities is mutually exclusive and BIRC3 abnormalities can recapitulate the genetics of ~40% chemorefractory and TP53 wild type CLL.

On these bases, BIRC3 disruption may contribute to expand the panel of biomarkers for the early identification of chemorefractory cases.\(^5\) In addition, BIRC3 abnormalities provide a molecular rationale for targeting NF-κB in poor risk and chemorefractory CLL. NF-κB inhibitors are under development in CLL and pre-clinical findings suggest that these compounds might be active against chemoresistant CLL clones.\(^6,68\)

### References:

1. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, JW WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. (Lyon, France, 2008).
2. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R., Kipps, T.J. and International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 111: 5446-5456. [http://dx.doi.org/10.1182/blood-2007-06-093906](http://dx.doi.org/10.1182/blood-2007-06-093906). PMid:18216293 PMCid:2972576
3. Damle, R.N., Wasi, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. and Chiorazzi, N., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999 94:1840-1847. PMid:10477712
4. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. and Stevenson, F.K., Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999 94:1848-1854. PMid:10477713
5. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ilbottson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. and Hamblin, T.J., Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002 100:1177-1184. PMid:12149195
6. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D.,...
Gaidano, G., Mutations of the SF3B1 splicing factor in chronic lymphocytic leukaemia. Nat Genet 2011 43: 1031-1036.

Rassenti, L.Z., Huynh, L., Toy, T.L., Chen, L., Keating, M.J., Gribben, J.G., Neuberg, D.S., Flinn, I.W., Rai, K.R., Byrd, J.C., Kay, N.E., Greaves, A., Weiss, A. and Kipps, T.J., ZAP-70 expression as a surrogate for prognosis of B-cell chronic lymphocytic leukaemia. N Engl J Med 2000 343: 1910-1916.

Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordonez, G.R., Villamor, N., Escarinas, G., Jares, P., Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordonez, G.R., Villamor, N., P., J. A. G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R., Hillmen, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, M., Child, Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child,
chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 370: 230-239. http://dx.doi.org/10.1016/S0140-6736(07)61125-3 PMid:18689542

25. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H. and Stilgenbauer, S., Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008 112: 3322-3329. http://dx.doi.org/10.1182/blood-2008-04-154070 PMid:18432826

26. Dicker, F., Herholz, H., Schmittge, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T. and Haferlach, C., The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009 23: 117-124. http://dx.doi.org/10.1038/leu.2008.274 PMid:19450740

27. Malickova, J., Smeradova, J., Roenova, L., Tichy, B., Kuglik, P., Vranova, V., Cejkova, S., Svitakova, M., Skuhrova Francova, H., Brychtova, Y., Dubek, M., Brejcha, M., Klabusay, M., Mayer, J., Pospisilova, S. and Trbusek, M., Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009 114: 5307-5314. http://dx.doi.org/10.1182/blood-2009-07-234708 PMid:19188171

28. Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gatelli, D., Capello, D., Forconi, F., Lauria, F. and Giudici, G., The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemoresistance. Clin Cancer Res 2009 15: 995-1004. http://dx.doi.org/10.1158/1078-0432.CCR-08-1630

29. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hofpinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Li, Y., Orlowski, R.Z., Malek, S.N., Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2012 http://dx.doi.org/10.1002/gcc.20975 PMid:22952040

30. Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Habe, S., Winkler, D., Buhler, A., Edelmann, J., Bergmann, M., Hofpinger, G., Hensel, M., Hallek, M., Dohner, H. and Stilgenbauer, S., TP53 mutation and survival in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010 376: 1164-1174. http://dx.doi.org/10.1016/S0140-6736(10)61381-5 PMid:20697090

31. Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Stamatopoulos, K., Arcaini, L., Lacioni, M., Rocque, G.B., Xu-Monette, Z.Y., Visco, C., Chang, J., Chigrinova, E., Forconi, F., Marasca, R., Besson, C., Papadaki, T., Paulli, M., Larocca, L.M., Pileri, S., Gatelli, D., Bertoncini, F., Foa, R., Young, K.H. and Gaidano, G., The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011 117: 3391-3401. http://dx.doi.org/10.1182/blood-2010-09-302174 PMid:22725381

32. Zaimuddin, N., Murray, F., Kanduri, M., Gunnarsson, R., Smedby, K.E., Enblad, G., Jurlander, J., Juliusson, G. and Rosenquist, R., ATM and STK11 mutations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012 97: 47-55. http://dx.doi.org/10.3324/haematol.2011.049270 PMid:21936760

33. Zenz, T., Krober, A., Scherer, K., Habe, S., Buhler, A., Denzel, T., Winkler, D., Edelmann, J., Schwanen, C., Dohner, H. and Stilgenbauer, S., Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009 115: 2589-2597. http://dx.doi.org/10.1182/blood-2009-05-224071 PMid:22493413

34. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. and Stilgenbauer, S., Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009 27: 3994-4001. http://dx.doi.org/10.1200/JCO.2008.21.1128 PMid:19643983

35. Zainuddin, N., Murray, F., Kanduri, M., Gunnarsson, R., Smedby, K.E., Enblad, G., Jurlander, J., Juliusson, G. and Rosenquist, R., STK11 mutations in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010 24: 2072-2079. http://dx.doi.org/10.1038/leu.2010.208 PMid:22297721

36. Pospisilova, S., Gonzalez, D., Malickova, J., Deambrogi, C., Zainuddin, N., Murray, F., Kanduri, M., Gunnarsson, R., Smedby, K.E., Enblad, G., Jurlander, J., Juliusson, G. and Rosenquist, R., Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009 27: 3994-4001. http://dx.doi.org/10.1200/JCO.2008.21.1128 PMid:19643983

37. Zenz, T., Habe, S., Denzel, T., Mohr, J., Winkler, D., Buhler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Dohner, H. and Stilgenbauer, S., Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and del(17p): final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012 30: 1647-1655. http://dx.doi.org/10.1200/JCO.2011.35.9695
45. Tam, C.S., Shanafelt, T.D., Wierda, W.G., Abruzzo, L.V., Van Dyke, D.L., O'Brien, S., Ferrajoli, A., Lerner, S.A., Lynn, A., Kay, N.E. and Keating, M.J., De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009 114: 957-964. http://dx.doi.org/10.1182/blood-2009-03-210591 PMid:20595516

46. Dreger, P., Dougher, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., Beelen, D., Zeis, M., Stadler, M., Hasenkamp, J., Uharek, L., Scheid, C., Hupke, N., Zenz, T., Winkler, D., Hallek, M., Knuts, M., Schmitz, N., Stilgenbauer, S. and German, C.L.L.S.G., Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010 116: 2438-2447. http://dx.doi.org/10.1182/blood-2010-03-275420 PMid:20697796 PMCid:2996483

47. Aster, J.C., Blacklow, S.C. and Pear, W.S., Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 2011 223: 262-273. http://dx.doi.org/10.1002/path.2789 PMid:21948802 PMCid:3132047

48. Lobry, C., Oh, P. and Afantis, I., Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 2011 210: 1931-1935. http://dx.doi.org/10.1084/jem.20111185 PMid:21646301 PMCid:3111955

49. Rothenberg, E.V., T cell lineage commitment: identity and renunciation. J Immunol 2011 186: 6649-6655. http://dx.doi.org/10.1101/cshperspect.a003707 PMid:22619094

50. Santos, M.A., Sarmento, L.M., Rebelo, M., Doce, A.A., Maillard, L., Dumortier, A., Neves, H., Radlje, F., Pear, W.S., Parreira, L. and Demengeot, J., NOTCH1 engagement by Delta-like-1 promotes +12 CLL. Haematologica 2012 97: 957-964. http://dx.doi.org/10.1182/hematol.2012-003707 PMid:23142775 PMCid:3493507

51. David, C.J. and Manley, J.L., Alternative pre-mRNA splicing regulation in cancer: pathways and programs unlinked. Gene Dev 2010 24: 2343-2364. http://dx.doi.org/10.1101/gad.1973010 PMid:20693832 PMCid:3132047

52. Luke, M.M., Della Setta, F., Di Como, C.J., Sugimoto, H., Kobayashi, R. and Arndt, K.T., The SAP, a new family of proteins, associate and function positively with the SIA1 phosphatase. Mol Cell Biol 1996 16: 2744-2755.

53. Wang, C., Chua, K., Seghezzi, W., Lees, E., Gozani, O. and Reed, R., Phosphorylation of splicing protein PAI5 coupled with splicing catalysis. Gene Dev 1998 12: 1409-1414. PMID:10400618 PMCid:48676

54. Das, B.K., Xia, L., Palandjian, L., Gozani, O., Chyang, Y. and Reed, R., Characterization of a protein complex containing splicing proteins SAPs 49, 130, 145, and 155. Mol Cell Biol 1999 19: 6706-6802. PMid:10238990

55. Wahl, M.C., Will, C.L. and Luhrmann, R., The spliceosome: design principles of a dynamic RNP machine. Cell 2009 136: 701-718. http://dx.doi.org/10.1016/j.cell.2009.02.009 PMid:19295386 PMCid:3322589

56. Papaemmanuil, E., Cazzola, M., Boultwood, J., Malovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J.S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., Godfrey, A.L., Rapado, I., Cvejic, A., Rance, R., Magee, C., Ellis, P., Mudie, L.J., Stephens, P.J., McLaren, L., Massie, C.E., Tarpey, P.S., Varela, I., Nik-Zainal, S., Davies, H.R., Shlien, A., Jones, D., Raine, K., Hinton, J., Butler, A.P., Teague, J.W., Baxter, E.J., Score, J., Galli, A., Della Porta, M.G., Travaglini, E., Groves, M., Tauro, S., Munshi, N.C., Anderson, K.C., El-Naggar, A., Fischer, A., Mustonen, V., Warren, A.J., Cross, N.C., Green, A.R., Futreal, P.A., Stratton, M.R., Campbell, P.J. and Chronic Myeloid Disorders Working Group of the International Cancer Genome, C., Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011 365: 1384-1395. http://dx.doi.org/10.1056/NEJMoa1103283 PMid:21990758

57. Li, X., Yang, X. and Ashwell, J.D., TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2011 472: 345-347. http://dx.doi.org/10.1038/nature09834 PMid:18997794 PMCid:766931

58. Zanevogel, B.J., Wang, Y., Mahoney, D.J., Dempsey, P.W., Cheung, H.H., He, J., Shiba, T., Yang, X., Yeh, W.C., Mak, T.W., Korneluk, R.G. and Cheng, G., Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nature Immunol 2008 9: 1371-1378. http://dx.doi.org/10.1038/nri1676

59. Vallabhapurapu, S. and Karin, M., Regulation and function of NF-kappaB transcription factors in the immune system. Mol Cell Biol 2009 29: 693-733. http://dx.doi.org/10.1146/annurev.immunol.021908.132641 PMid:20489833 PMCid:2964333

60. Conze, D.B., Zhao, Y. and Ashwell, J.D., Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biol 2010 8: e1000518. http://dx.doi.org/10.1371/journal.pbio.1000518

61. Hewamana, S., Lin, T.T., Jenkins, C., Burnett, A.K., Jordan, C.T., Fegan, C., Brennan, P., Rowntree, C. and Pepper, C., The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res 2008 14: 8102-8111. http://dx.doi.org/10.1158/1078-0432.CCR-08-1672 PMid:20351313 PMCid:2904580

62. Hertlein, E., Wagner, A.J., Jones, J., Lin, T.S., Maddocks, K.J., Towns, W.H., 3rd, Goettl, V.M., Zhang, X., Jarioua, D., Raymond, C.A., West, D.A., Croce, C.M., Byrd, J.C. and Johnson, A.J., 17-DMAg targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010 116: 45-53. http://dx.doi.org/10.1182/blood-2010-01-263756